Will It Go Up in 2021?

Avalon GloboCare (AVCO) stock is down 15 percent year-to-date and 42 percent from its 52-week high. The big drop is mostly the result of a sell-off in penny and speculative high-growth stocks as investors rebalance their portfolios. What’s the forecast for AVCO stock in 2021? Will it go up, and is it a good penny stock to buy now?

Avalon GloboCare is an intelligent biotech developer and provider of healthcare services. Regenerative therapeutics, cell-based immunotherapy (including CAR-T/NK), exosome technology, and rehabilitation medicine are all part of its technological and service ecosystem. Avalon also focuses on diagnostic advancements in the fields of cancer, infectious diseases, and fibrotic disorders.

The Avalon-SenlangBio merger update

Avalon has entered into a definitive agreement to acquire Hebei Senlang Biotechnology. SenlangBio is a leading cell therapy company based in Northern China. Under the terms of the deal, Avalon will offer 81 million of its common shares to buy SenlangBio. This transformative acquisition is expected to contribute significantly to Avalon’s growth and development.

Article continues below advertisement

Source: Pixabay

In a press release, Avalon said, “the Acquisition will add SenlangBio’s diverse and broad pipeline covering solid tumors and hematologic malignancies, including both autologous and universal (“off-the-shelf”) cell therapy programs.” The company added, “SenlangBio’s intellectual property includes 10 issued patents and 5 patents pending in China, as well as multiple know-how Ips.”

Article continues below advertisement

avalon globocare avco stock forecast

Source: Pixabay

Article continues below advertisement

View more information: https://marketrealist.com/p/avalon-globocare-avco-stock-forecast-2021/

See more articles in category: Finance

Leave a Reply

Back to top button